<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055012</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19010007</org_study_id>
    <nct_id>NCT04055012</nct_id>
  </id_info>
  <brief_title>Effects of Metformin on Low Back Pain</brief_title>
  <official_title>Metformin and Beyond: Individualizing Care for Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gwendolyn Sowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to determine the effects of metformin in non-diabetic
      patients with low back pain, and identify novel targets for future treatments
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    FDA Recall of Metformin
  </why_stopped>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Numeric Pain Rating Scale</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 10 with a higher score indicating more severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Oswestry Disability Index</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0% to 100% with higher percentage scores indicating greater disability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Connor-Davidson Resilience Scale 25</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 100 in which a higher score demonstrates greater resilience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 10 Meter Walk Test</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Subject is timed walking at normal speed and also fastest speed possible. A faster time is associated with better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fear Avoidance Questionnaire</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 96 in which a higher score indicates greater fear avoidance beliefs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Godin Leisure Time Questionnaire</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Minimum score is 0 and there is no maximum score. A higher score indicates a more active individual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Catastrophizing Scale</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Score range from 0 to 36 with a higher score indicating a higher degree of catastrophizing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Generalized Anxiety Disorder-7</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 21 with a higher score indicating more anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PROMIS (Patient-Reported Outcomes Measurement Information System) 16 Questionnaire</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>This questionnaire is scored on the T-score metric. A higher score indicates a greater amount of whatever concept that the question asks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Health Questionnaire-9</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 27 with higher scores indicating more depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-5D-5L (EuroQol)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 5 to 25 with higher scores indicating more problems. Scores on the visual analogue scale range from 0 to 100 with 100 being the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in McGill Pain Questionnaire</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Scores range from 0 to 45 with a higher score indicating more pain.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>High Dose Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1 metformin tab (500mg) and 1 placebo tab in pre-packaged blister pack) for the first week then increase to 3 tabs per day (1 metformin tab (500mg) and 2 placebo tabs (in pre-packaged blister pack) for the remaining 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group (n=100). Subjects will receive placebo and will be instructed to take 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-List Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month &quot;waiting period&quot; before they will be randomized again to a treatment group. They will be randomized to one of the previous groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500mg tabs of Metformin Extended Release</description>
    <arm_group_label>High Dose Metformin</arm_group_label>
    <arm_group_label>Low Dose Metformin</arm_group_label>
    <arm_group_label>Wait-List Control</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>Metformin Extended Release</other_name>
    <other_name>Metformin ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tabs</description>
    <arm_group_label>Low Dose Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Wait-List Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and above

          -  Diagnosed with axial low back pain (low back pain more severe than pain in other parts
             of the body, without radiation of pain into the lower extremities).

          -  Women of child bearing potential must have a negative serum pregnancy test at
             baseline.

        Exclusion Criteria:

          -  Diagnosed with rheumatoid arthritis, lupus, other autoimmune/systemic inflammatory
             arthropathies

          -  Progressive lower extremity weakness or numbness

          -  Recent oral steroid use (within last 3 months)

          -  NSAID use

          -  Chronic kidney disease (eGFR &lt;60)

          -  Diagnosis of diabetes mellitus

          -  Subjects must not be pregnant or breastfeeding, or planning to become pregnant or
             breastfeed during the course of the trial

          -  Unable to take an oral medication in a non crushable pill form

          -  Taking metformin presently or within the last 6 months

          -  History of allergy to metformin

          -  History of lactic acidosis

          -  Severe Hepatic dysfunction

          -  Currently taking a diabetic medication such as sitagliptin, saxagliptin, linagliptin,
             alogliptin, sitagliptin with metformin

          -  Currently taking a Carbonic anhydrase inhibitor such as topiramate, zonisamide,
             acetazolamide, dichlorphenamide, methazolamide

          -  Currently taking cimetidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwendolyn Sowa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Kaufmann Medical Building</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Wexford Spine Center</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Gwendolyn Sowa</investigator_full_name>
    <investigator_title>Professor and Chair Department of Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>Low Back Pain</keyword>
  <keyword>Metformin</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

